natgillin/translations-raw huggingface dataset:
Before placing the container in the chill chamber of the drink dispenser, the dispensing channel is likewise closed by means of a spring-loaded valve. 
Prije smještanja spremnika u hladnu komoru djelitelja pića, kanal raspršivača je zatvoren na sličan način pomoću ventila na oprugu.
The method of claim 6, wherein the human Vk-Jk intergenic region sequence comprises SEQ ID NO: 100. The method of claim 1, the mouse further comprises an immunoglobulin heavy chain allele comprising human VH, DH, and JH gene segments operably linked to an endogenous mouse heavy chain constant region gene such that the mouse expresses an immunoglobulin heavy chain that comprises a human heavy chain variable domain sequence fused with a mouse heavy chain constant domain. 
Genetski modificirani miš prema zahtjevu 1, naznačen time, što miš u svom genomu dodatno sadrži endogeni lokus imunoglobulina lakog lanca K koji se sastoji od zamjene endogenih VK 1 JK genskih segmenta neraspoređenim humanim VA i JA genskim segmentima, te naznačen time, što su humani VA 1 JA genski segmenti operativno povezani s endogenim mišjim CK genom tako da miš izražava imunoglobulinski laki lanac koji sadrži humanu varijabilnu regiju A spojenu s mišjom konstantnom regijom K.
The method of claim 8, wherein the human IgG4 constant region comprises the amino acid sequence of SEQ ID NO: 12, and the human k light chain constant region comprises the amino acid sequence of SEQ ID NO: 13. 
Protutijelo ili njegov ulomak koji veže antigen za uporabu prema zahtjevu 8, naznačen time što humana IgG4 konstantna regija sadrži aminokiselinsku sekvencu iz SEQ ID NO: 12, i humana k konstantna regija lakog lanca sadrži aminokiselinsku sekvencu iz SEQ ID NO: 13.
Use of a compound as claimed in of any one of claims 1-12, or a pharmaceutically acceptable salt, or solvate thereof, in the manufacture of a medicament for treating stroke, neuronal damage resulting from head trauma, epilepsy, seizures, neuronal loss following global and focal ischemia, pain, migraine, primary erythromelalgia, paroxysmal extreme pain disorder, cerebellar atrophy, ataxia, mental retardation, a neurodegenerative disorder, manic depression, tinnitus, myotonia, a movement disorder, or cardiac arrhythmia, or providing local anesthesia in a mammal, comprising administering an effective amount of said compound and, wherein preferably said use is for treating pain, and wherein even more preferably said use is for preemptive or palliative treatment of pain or ii) said pain is selected from the group consisting of chronic pain, inflammatory pain, neuropathic pain, acute pain, and surgical pain. 
Uporaba tvari u skladu s bilo kojim od patentnih zahtjeva 1-12, ili njene farmeceutski prihvatljive soli ili solvata, u proizvodnji lijeka za liječenje moždanog udara, neurološkog oštećenja nastalog uslijed traume glave, epilepsije, konvulzija, gubitka neurona nakon globalne i fokalne ishemije, boli, migrene, primarne eritromelalgije, paroksizmalnog ekstremnog poremećaja boli, ocerebelarne - atrofije, ataksije, "mentalne retardacije, neurodegenerativnog poremećaja, manične depresije, tinitusa, miotonije, poremećaja pokretanja, srčane aritmije, ili davanja lokalne anestezije sisavcima, obuhvaćajući primjenu učinkovite količine navedene tvari i, gdje je poželjna od navedenih uporaba tretiranje boli i gdje je još poželjnija i) = navedena uporaba prvotno ili palijativno liječenje boli; ili ii) navedena uporaba je odabrana 1z grupe koja se sastoji od kronične boli, upalne boli, neuropatske boli, akutne boli i kirurške boli.
The present light stabilising composition is particularly effective in preventing the development of sunstruck flavour in beer, especially in beer that is stored in a container that is transparent to light, particularly a container that is transparent to light with a wavelength in the range of 330-360 nm, more particularly a container that is transparent to a wider spectrum of light within the range of 320-400 nm. 
Sadašnji pripravak za stabiliziranje na svjetlo je naročito djelotvoran za sprečavanje razvoja užegle arome u pivu, naročito u pivu koje je pohranjeno u spremniku koji je propustan za svjetlo, naročito u spremniku koji je propustan za svjetlo valne duljine u opsegu od 330-360 nm, još naročitije u spremniku koji je propustan za širi spektar svjetla unutar opsega od 320-400 nm. HR P20070273 T3
A compound of claim 21, wherein the viral infection is selected from the group consisting of: hepatitis B, hepatitis C, human immunodeficiency virus, Polio, Coxsackie A and B, Rhino, Echo, small pox, Ebola, and West Nile virus. 
Spoj u skladu s patentnim zahtjevom 21, naznačen time što se virusnu infekciju bira iz skupine koju čine: virus hepatitisa B, virus hepatitisa C, virus ljudske imunodeficijencije, poliovirus, coxsackie virus A i B, rinovirus, ECHO-virus, velike boginje, Ebola i virus zapadnog Nila.
A dry powder inhaler device, containing a dry powder formulation according to claim 9 . 
Inhalator za suhi prašak napunjen formulacijom suhog praška iz bilo kojeg od patentnih zahtjeva 8 do 12.
installing a supply for liquid plastic material, for instance synthetic resin; 
- - priključenje dovoda tekućeg plastičnog materijala, na primjer sintetičke smole;
A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I and one or more pharmaceutically acceptable carriers, diluents and excipients, the compound of formula I having the following structure: 
Farmaceutski sastav obuhvaća terapijski učinkovitu količinu tvari iz patentnog zahtjeva 1 1 jedan ili više farmaceutski prihvatljivih nosača, diluenata i ekscipijenasa.
These polymers have a viscosity at 25° C. of 4500 to 17600 cP, measured on a 5 wt. % aqueous solution using a model RVF Brookfield viscosimeter (spindle no. 2/rotational speed 2 rpm), of 400 to 4000 cP, measured on a 2 wt. % aqueous solution using the stated viscosimeter (spindle no. 1 or 3/rotational speed 10 rpm) or of 1650 to 10000 cP, measured on a 1 wt. % aqueous solution using the stated viscosimeter (spindle no. 2/rotational speed 2 rpm). 
Ovi polimeri imaju viskozitet kod 25C od 4500 do 17600 cP, mjereno na 5 tež.% vodenoj otopini pomoću Brookfield viskozimetra, model RVF (vreteno br. 2 / brzina rotacije 2 o/min), od 400 do 4000 cP, mjereno na 2 tež.% vodenoj otopini pomoću HR P20070272 T3 navedenog viskozimetra (vreteno br. 1, odnosno 3/ brzina rotacije 10 o/min), odnosno od 1650 do 10000 cP, mjereno na 1 tež.% vodenoj otopini pomoću navedenog viskozimetra (vreteno br. 2 / brzina rotacije 2 o/min).
measuring the amount of the conjugate delivered across the endothelial cells. 
mjerenje količine konjugata isporučenog preko endotelijalnih stanica.
8 shows a heat exchanger 70 that forms part of the beer line with an inflow end 71 that is connected to the container 3 and an outflow end 72 for dispensing beer. 
SI. 8 prikazuje izmjenjivač topline 70 koji čini dio linije za pivo s ulaznim krajem 71 koji je spojen na spremnik 3 i izlaznim krajem 72 za izdavanje piva.
An agent of the invention may be mixed with the other drug substance in a fixed pharmaceutical composition or it may be administered separately, before, simultaneously with or after the other drug substance. 
Sredstva izuma mogu se miješati s drugim ljekovitim tvarima u fiksnom farmaceutskom sastavu ili se mogu dati odvojeno, prije, istovremeno ili nakon druge ljekovite tvari.
In practice, it has been found that the invention thus described solves the problems noted in known types of food packaging sheet. 
U praksi je pronadeno da ovako opisan izum rješava probleme opažene kod poznatih tipova folija za pakiranje hrane.
The solid form of the compound of claim 8 which is: crystalline; or 
Čvrsti oblik spoja prema patentnom zahtjevu 15 koji se nalazi u obliku kristala.
R8, when present, is H or optionally substituted C1-C4 alkyl; 
Reg, kada je prisutan, je H ili izborno supstituirani C,-C, alkil;
The tube of claim 13, wherein the elongated baffle members are separated from the elongated electrodes by way of a ceramic spacer. 
Cijev u skladu s patentnim zahtjevom 8, naznačena time, da su izduženi pregradni elementi (204a, 204b) odvojeni od izduženih elektroda (203a, 203b) keramičkom razmaknicom (338).
In some embodiments, the condition is a skin disease or disorder, sepsis, dermatitis, osteoarthritis, cancer, inflammation, an autoimmune disease, inflammatory bowel disease, a complication from localized or total-body exposure to ionizing radiation, mucositis, acute or chronic organ failure, liver disease, pancreatitis, an eye disorder, a lung disease or diabetes. 
Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 27-29, naznačen time da je stanje kožna bolest ili poremećaj, sepsa, dermatitis, osteoartritis, rak, upala, autoimuna bolest, upalna bolest crijeva, komplikacija od lokaliziranog izlaganja ili izlaganja cijelog tijela ionizirajućem zračenju, mukozitis, akutno ili kronično zatajenje organa, bolest jetre, pankreatitis, poremećaj očiju, plućna bolest, ili dijabetes.
The gastroretentive drug formulation of claim9, wherein 70 mg of the levodopa and 25 mg carbidopa are formulated as an immediate release component, whereas the rest of the carbidopa and the levodopa are released in a controlled manner over 8-10 hours. 
Oblik lijeka koji se zadržava u želucu iz patentnog zahtjeva 6, pri čemu su 70 mg levodopa i 25 mg karbidopa oblikovani kao sastavnica koja se izravno otpušta, dok se ostatak karbidopa i levodopa otpušta kontrolirano kroz 8-10 sati.
The antibody of any one of items 1 to 5, which is not substantially capable of binding to CLDN4 associated with the surface of a cell that expresses CLDN4 and/or is not substantially capable of binding to CLDN3 associated with the surface of a cell that expresses CLDN3. 
Antitijelo suglasno zahtjevima 1 ili 2, naznačeno time da nije u biti sposobno da se veže za CLDN4, koji je asociran na membrani stanice koja eksprimira CLDN4 i/ili nije u biti sposobno da se veže za CLDN3 asociranim za membranu stanice koja eksprimira CLDN3.
An isolated nucleic acid molecule encoding the antibody or antigen-binding portion of any one of claims 1 to 6, or an expression vector comprising said nucleic acid, or a host cell comprising said expression vector. 
Molekula izolirane nukleinske kiseline koja kodira protutijelo ili dio koji veže antigen prema bilo kojem od zahtjeva 1 do 4. Vektor ekspresije koji sadrži molekulu nukleinske kiseline prema zahtjevu 9.
wherein the body comprises a fixed portion and a mobile portion, for being fixed in a plurality of positions relative to the fixed portion, so as to change a configuration of the profile; 
pri čemu tijelo (104) sadrži fiksni dio (110) i pokretni dio (112), za fiksiranje u više položaja u odnosu na fiksni dio (110), tako da se promijeni konfiguracija profila;
The method according to any one of claims 1 to 14, wherein the autoantibody is selected from a DNA-specific autoantibody, a tubulin-specific autoantibody, and a thyroglobulin-specific autoantibody. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačen time što se autoprotutijelo bira između autoprotutijela specifično za DNA, autoprotutijela specifičnog za tubulin, te autoprotutijela specifičnog za tireoglobulin.
In one advantageous embodiment, an agent for blocking the free lanthanide, other than the free macrocyclic chelate, is added in step b). 
Postupak prema bilo kojem zahtjevu od 1 do 14, naznačen time da se sredstvo za blokiranje slobodnog lantanida, poželjno polikarboksilna kiselina, dodaje u koraku b).
Plasmatic lipids and oxidative stress parameters (mean ± s.d.) 
Parametri lipida u plazmi i oksidativan stres (prosjek + s.d.)
Mill (20) according to Claim 1 or 2, wherein opening of the hatch (42) is automatically controlled depending on the temperature in the rotating mass of waste R. 
Mlin (20) sukladno zahtjevu 1 ili 2, pri čemu je otvor (42) automatski kontroliran ovisno o temperaturi rotirajuće mase otpada R.
A process for the production of frames (27c) from material such as wire or strip or other material of prismatic cross section as claimed in any one of claims 9 to 13, further characterized by: 
Proces proizvodnje okvira (27c), od materijala, kao što su žica, ili traka ili drugi materijali prizamtičnog poprečnog presjeka, prema zahtjevima 9 do 13, dalje naznačen time:
A compound according to any one of claims 1 to 6 which is in the form of a free base. 
Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je u obliku slobodne baze.
A compound according to claim 1 having the structural formula: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da ima strukturnu formulu:
a fragment of the Bordetella pertussis CyaA protein as set forth in SEQ ID NO: 2, the sequence of said fragment beginning with the first residue of SEQ ID NO:2 and ending with a residue located from position 183 to position 227 of SEQ ID NO:2, or a variant with at least 95% similarity with this fragment; 
fragmenta proteina CyaA iz bakterije Bordetella pertussis kao što je iznijet u SEQ ID NO:2, gdje slijed navedenog fragmenta počinje prvim ostatkom u SEQ ID NO:2, a završava ostatkom koji se nalazi od položaja 183 do položaja 227 u SEQ ID NO:2;
THCV alone or in combination with CBD for use in the treatment of generalised seizures and / or partial seizure as claimed in claim 1 or 2 wherein the THCV is present in amount which provides a daily dose of least 1.5mg. 
Kanabidiol (CBD) za primjenu u liječenju parcijalnih napadaja naznačen time da je CBD prisutan u količini koja osigurava dnevnu dozu od najmanje 400mg.
passing a gaseous stream comprising said 1,2-unsaturated carbonylic compound to be hydrogenated and hydrogen over a palladium catalyst comprising a carrier and palladium, wherein said catalyst has a heterogeneous distribution of palladium, palladium being concentrated to the outermost surface of the catalyst, which outermost surface is being exposed to the surrounding; wherein the temperature over said catalyst is 120 to 200°C and the pressure over said catalyst is at least 0.1 MPa; and said 1,2-unsaturated carbonylic compound is an aldehyde according to structural formula (II), wherein R1, R2 and R3, independently of each other, are selected from the group consisting of hydrogen and C1-4 alkyl. 
prolazak plinovite struje koja sadrži navedenu 1,2-nezasićenu karbonilnu tvar koju treba hidrogenirati i vodik preko paladijskog katalizatora koji sadrži nosač i paladij, pri čemu navedeni katalizator ima heterogenu raspodjelu paladija, paladij je koncentriran na vanjskoj površini katalizatora, a ta je vanjska površina izložena okolišu; pri čemu je temperatura preko navedenog katalizatora 120 do 200°C i tlak preko navedenog katalizatora je najmanje 0.1 MPa; i navedena 1,2 nezasićena karbonilna tvar je aldehid prema strukturnoj formuli (II), [image] gdje su R1, R2 i R3, nezavisno jedan od drugog, odabrani iz grupe koja se sastoji od vodika i C1-4 alkila.
The mixture was then stirred for 5 h at 65-70° C. After cooling to room temperature the product was filtered off and washed with 40% methanol solution. 
Mješavina je tada miješana tijekom 5 h na 65-70*C. Nakon hlađenja do sobne temperature, produkt je filtriran i opran s 40% otopinom metanola.
for a compound of Formula I where X is S, coupling a corresponding compound having the formula II 
(b) za spoj s formulom I gdje X je S, sparivanje odgovarajućeg spoja koji ima formulu II Ri Rb
a decoder to be configured to parse from the bitstream transformation coefficients generated by transformation according to the at least one transformation unit generated by dividing the coding unit, and reconstruct residual of the at least one transformation unit by performing inverse quantization, and inverse transformation on the parsed transformation coefficients, perform intra prediction or inter prediction on the at least one prediction unit to generate a predictor, and reconstruct the image based on the residual and the predictor, wherein: 
Postupak dekodiranja slike, te postupak sadrži: određivanje mnoštva kvadratnih maksimalnih kodirajućih jedinica u slici na osnovu informacija o maksimalnoj jedinici kodiranja izdvojenoj iz toka bitova, određivanje kvadratne jedinice kodiranja koja je hijerarhijski razdvojena iz maksimalne jedinice kodiranja na osnovu informacija o jedinicama kodiranja izdvojenim iz toka bitova, dobivanje kvantiziranih koeficijenata transformacije za transformacijsku jedinicu u jedinici kodiranja provođenjem entropijskog dekodiranja na toku bitova koji je kodiran na temelju jedinice kodiranja;
A method according to claim 15, wherein an additional antisense oligonucleotide is used which is able to induce or promote skipping of at least one of exon 51, 53, 55, 57, 59 or 69 of the dystrophin pre-mRNA of a patient. 
Besmisleni oligonukleotid u skladu s bilo kojim od patentnih zahtjeva 1-14, vektor iz patentnog zahtjeva 15, ili farmaceutski sastav iz patentnog zahtjeva 16, za induciranje ili promoviranje preskakanja eksona 45 za uporabu u liječenju pacijenta s DMD ili BMD.
A compound as claimed by claim 1, wherein said compound is radiolabeled. 
Spoj prema zahtjevu 1, naznačen time da je navedeni spoj radio-označen.
A light source as claimed in claim 14, the aperture being no bigger than one tenth of the free space wave length of the microwaves in the body. 
Svjetlosni izvor u skladu s patentnim zahtjevom 9, naznačen time, da navedeni otvor nije veći od jedne desetine valne duljine mikrovalova u slobodnom prostoru unutar retorte.
The pyrazole (AB) can be saponified using methods known to one of skill in the art, for example, treating with aqueous sodium hydroxide in a solvent mixture such as THF/MeOH. 
Pirazol (AB) se može saponificirati uporabom postupaka poznatih stručnjacima iz struke, na primjer, tretiranjem s vodenom otopinom natrij hidroksida u smjesi otapala poput THF/MeOH.
Example 1: Generation of the expression plasmids 
Datum podnošenja europske prijave patenta:
from 5 to 50 µg/mL palonosetron hydrochloride based on the weight of the free base; 
do 50 µg/mL palonosetron hidroklorida na osnovu težine slobodne baze;
A mouse cell comprising in its genome an endogenous λ light chain immunoglobulin locus comprising a deletion of the endogenous mouse Vλ1-Jλ3-Cλ3-Jλ1-Cλ1 gene cluster and a deletion of a region spanning from Vλ2 to Jλ2 of the endogenous mouse Vλ2-Vλ3-Jλ2-Cλ2-Jλ4-Cλ4 gene cluster, wherein the endogenous λ light chain immunoglobulin locus retains endogenous Cλ2, Jλ4 and Cλ4 gene segments. 
Mišja stanica koja u svom genomu sadrži endogeni lokus imunoglobulina lakog lanca A koji se sastoji od brisanja endogenog mišjeg VM -JX43-C23-JM-CM klastera gena 1 brisanja regije koja se proteže od VA2 do JM2 endogenog mišjeg VA2-V23-JX2-C12-IA4-CI4 klastera gena, naznačena time, što endogeni lokus imunoglobulina lakog lanca X zadržava endogene C22, JA4 1 CH4 genske segmente.
wherein A, R2 are as defined in claim 1; 
[image] naznačeno time da su A, R2 definirani kao u zahjevu 1:
A method for identifying or screening molecules useful in the treatment of a centronuclear myopathy, preferably XLCNM, comprising the steps of: providing or obtaining a candidate compound; and determining whether said candidate compound inhibits the activity, function and/or expression of Dynamin 2, 
Postupak identificiranja ili probira molekula korisnih u liječenju centronuklearne miopatije, po mogućnosti XLCNM, naznačen time što se sastoji u koracima: a. - osiguravanja ili dobivanja spoja kandidata; i b. - određivanja pokazuje li navedeni spoj kandidat aktivnost, funkciju i/ili eksprimiranje dinamina 2; c.
The polymorph of 6-(Piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride as claimed in claim 4, which is polymorph 1 and has at least reflections in an X-ray powder diffractogram using CuKa1 radiation at, 15.4, 16.8, 21.7, 22.8 and 24.7 degrees 2theta ± 0.2 degrees 2theta. 
Polimorf 6-(piperidin-4-iloksi)-2H-izokinolin-1-on hidroklorida prema zahtjevu 4, naznačen time da je polimorf 1 i ima refleksije u difraktogramu X-zraka na prahu korištenjem CuKo, zračenja barem kod 4.5, 15.4, 16.8, 21.7, 22.81 24.7 stupnjeva 2theta + 0.2 stupnjeva 2theta.
Such locks are described, for example, in U.S. Pat. Nos. 5,520,035, 5,784,910 and 5,839,308 to Eizen et al., assigned to the assignee of the present application. 
Takvc su brave opisane, npr. u US Patentima 5520035, 5784910 1 5839308 za Eizen et al., koji su pripisani podnositelju ove prijave.
Also, the use of acoustical warnings may be considered, such as buzzers or the like. 
Osim toga, može se razmisliti i nekom tipu zvučnog upozorenja, npr. zujalo ili sl.
A combination for use according to claim 15 where the opioid receptor ligand comprises morphine. 
Sastav za uporabu prema zahtjevu 15 naznačen time da ligand opioid receptora sadrži morfin.
The Compound of Claim 3 where R1 is optionally substituted alkyl or cycloalkyl; or a single stereoisomer or mixture of stereoisomers thereof and optionally as a pharmaceutically acceptable salt or solvate thereof. 
Spoj prema patentnom zahtjevu 3, naznačen time što je R1 jednako izborno supstituirani alkil ili cikloalkil; ili njegov pojedinačni stereoizomer ili smjesa stereoizomera i izborno kao njegova farmaceutski prihvatljiva sol ili solvat.
The composition for use according to any one of the preceding claims, wherein the eye disease, disorder or condition is selected from AMD, PU, BRVO, CRVO, DME, CME, UME, CMV retinitis, endophthalmitis, inflammation, glaucoma, macular degeneration, scleritis, choriotetinitis, Dry eye syndrome, Stargardt disease, Norris disease, Coat's disease, persistent hyperplastic primary vitreous, familial exudative vitreoretinopathy, Leber congenital amaurosis, Retinitis Pigmentosis, X-linked retinoschesis, Leber's hereditary optic neurophathy (LHON), and/or uveitis, optionally wherein the composition is administered (a) once a week, (b) twice a month, or (c) once a month. 
Pripravak za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što je bolest oka, poremećaj ili stanje odabrano od AMD, PU, BRVO, CRVO, DME, CME, UME, CMV retinitisa, endoftalmitisa, upale, glaukoma, makularne degeneracije, skleritisa, korioretinitisa, sindroma suhog oka, Stargardtove bolesti, Norisove bolesti, Coatove bolesti, perzistentne hiperplastične primarne vitreoze, obiteljske eksudativne vitreoretinopatije, Leberove urođene amauroze, retinitisa pigmentoza, X-vezane retinoshize, Leberove nasljedne optičke neuropatije (LHON) 1 uveitisa, proizvoljno, pri čemu se pripravak primjenjuje (a) jednom tjedno, (b) dva puta mjesečno ili (c) jednom mjesečno.
This is often done by collecting and grinding the plastics material bottles. 
To se često radi skupljanjem i mljevenjem boca iz plastičnog materijala.
The compound according to any one of claims 1 to 6 or the composition according to claim 7, for use in the treatment of excess weight in a mammal, preferably a human being. 
Tvar u skladu s bilo kojim od patentnih zahtjeva 1 do 6 ili sastav u skladu s patentnim zahtjevom 7, za uporabu u liječenju prekomjerne težine kod sisavaca, poželjno kod ljudskih bića.